GlassScriptPhysician profile
Farhad Naseh
NPI 1710176763
$4,860.91
in general payments reported to CMS, 2019-2025
32 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $180 · 2021: $584 · 2022: $720 · 2023: $658 · 2024: $961 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $745.68 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Sun Pharmaceutical Industries INC. | $635.75 | 2019-2025 | Cequa |
| Abbvie INC. | $349.76 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $334.28 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $317.03 | 2024-2025 | Xdemvy |
| Allergan, INC. | $301.24 | 2019-2022 | |
| Amgen INC. | $222.96 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $208.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $180.68 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $146.12 | 2024-2025 | Vevye, Triesence |
| Novartis Pharmaceuticals Corporation | $136.62 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.05 | 2019-2021 | |
| Shire North American Group INC | $109.17 | 2019 | |
| Dompe US, INC. | $98.43 | 2019-2022 | |
| Glaukos Corporation | $97.93 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $97.16 | 2022-2025 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $92.85 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $75.22 | 2022-2024 | Acuvue |
| Kala Pharmaceuticals, INC. | $73.93 | 2021-2022 | |
| Abb Con-Cise Optical Group LLC | $68.96 | 2020 | |
| Thea Pharma INC. | $66.54 | 2023-2025 | Iyuzeh |
| Rxsight INC | $64.09 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Genentech USA, INC. | $61.92 | 2022-2025 | Vabysmo |
| Horizon Therapeutics Plc | $34.40 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $33.54 | 2019 | |
| Coherus Oncology, INC. | $33.31 | 2023 | |
| Coopervision INC. | $32.21 | 2019-2024 | Myday Contact Lens |
| Mallinckrodt Hospital Products INC. | $26.79 | 2025 | Acthar |
| Sandoz INC. | $25.17 | 2024 | Cimerli |
| Ocular Therapeutix, INC. | $24.27 | 2019 | |
| Biotissue Holdings INC. | $20.44 | 2024 | |
| Omeros Corporation | $15.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Naseh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.